Presentation 3Q17

1. 3Q17 Earnings Release

2. 3Q17 | Capital Allocation Strategy

3. Profarma
2017 | Focus in profitability
3
Company in
Ramp up
Pharma Market
Increasing
FOCUS: ROIC AND NET INCOME
Sharp drop in
Interest Rate
Inflation
Decreasing
Better return
Segments
Ebitda Margin
Evolution
Capital
Reallocation
Dilution of
Operating Costs
2017
2018

4. Profarma | Histórico Alocação de Capital
Profarma
Verticalização | Vantagens do Modelo Integrado
4
Drugstore Market
✓
Wholesalers with lower dependence on
big chains and market share growth with
higher rates.
Lower Working Capital
✓
Optimized working capital and a cash
cycle 30 days shorter than the average of
other retail players.
Supply Agility
✓
Integrated logistic structure enables a
promptly accelerated inventory recovery
in various regions.
Relevance to Suppliers
✓
Combined purchsing power between
retail and wholesale assures more
competitive prices.
Tax Optimization
✓
More competitive prices when buying
inside the state directly from the
wholesale.
G&A Sinergies
✓
Shared Services Center: legal, fiscal,
internal audit and human resources.
Distribution center shared with wholesale
clients – 35 thousand clients supplied
nationally.

5. 10.8% 10.9% 10.9%
12.2%
13.4% 14.0% 14.3%
Profarma | Histórico Alocação de Capital
Profarma
2016 - 2017 | Capital Allocation Strategy for Best Return Segments
Invested Capital Evolution – Profarma Group
(R$ million)
Pharma: 10.6% - last 5 years average.
Specialties: 12.6% - last 5 years average for a adjusted EBITDA margin of 3.2%.
Retail: 19.2% - top 3 players average.
Consolidated: Weighted average potential ROIC, considering each division’s potential ROIC.
5
POTENTIAL
ROIC
625 631 662 776
578 571
709
41 68
101
53 68
96
156
272
389
571
625 672 730
1,032
903
1,028
1,376
2010 2011 2012 2013 2014 2015 2016
Farma ROIC Potencial ConsolidadoEspecialidades Varejo
771 702
98
106
421 667
1,291
1,475
3Q16 3Q17
13.6%
14.6%
Invested Capital: Equity + Net Debt
ROIC: NOPAT /Invested Capital

6. Profarma | Histórico Alocação de Capital
Profarma
Marginal ROIC – New Stores and Renovated Stores Rede Rosário
6
Market Rede Rosário - Integrated Model
Ramp up
Sales 12 m
Gross Profit 100 100
Gross Margin 30.1 31.0
Operating Expenses - Store 16.5 1
Contribution Margin - Store 13.6 30.0
NOPAT 10.1 21.2
Capex 15.7 20.8
Working Capital 6.5 3.1
Pre-Operational Expenses 2.4
Total Invested 24.6 23.9
Marginal ROIC % (Standard Income Tax) 40.9% 88.8%
Marginal ROIC - New Stores | Pharma Retail | Base 100
R$ thousand
√ Does not include Investment in D.C.
√ Does not include Investing in D.C. Stock

7. Profarma | Histórico Alocação de Capital
Profarma
Consolidated | 3Q17 Non Recurring Expenses vs Savings
7
Division Action/Iniciative
Estimate Savings
(annual, except PERT)
3Q17 Non Recurring
Expenses
Closing DC Ceará and Change of from Espírito Santo to Rio de
Janeiro
R$ 4.2MM R$ 1.5MM
Operating productivity gains - Logistics/Commercial R$ 5.6 MM R$ 1.2MM
Stores operating expenses reduction d1000 RJ R$ 9.1MM R$ 3.1MM
Corporate expenses reduction R$ 12.0MM R$ 2.1MM
Closing 33 stores: Negative Contribution Margin R$ 6.5MM R$ 11.3MM
Consolidated PRFM joined the new refinacing program for Federal taxes (PERT)*¹ R$ 32.6MM R$ 1.9MM
Total 3 Years Savings R$ 144.8MM R$ 21.2MM
Pharma
Retail

8. Profarma
Rosário Performance
Financial Indicator
8
(18.9)
(11.9)
Operating Indicator
(6.3)
(0.6)
Monthly average sale 3Q17 - RosárioDez/16 Sep/17 - RosárioSep/16
165
340
537
56
92 92
573
655
1,700
43
55
39
Sep/17 – d1000 varejo farma RJ
Operating Expenses
(R$ Million)
Ebitda
(R$ Million)
Monthly average sale
(R$ thousand)
Service level
(%)
Clients served
(# thousand)
Average Ticket
(R$)

9. Consolidated Performance

10. Profarma | Histórico Alocação de Capital
Profarma
3Q17 | Key Highlights
10
PROFARMA GROUP | CONSOLIDATED
• Gross revenue rose by 4.5%.
• The consolidated cash cycle was shortened by 16.0
days to 35.2 days.
• The Retail Division accounted for about 55% of our
consolidated gross profit, vs. 40% in 3Q16.
• The Independent customers segment grew by 8.6%.
• Sales of health & beauty products climbed by 44.6%.
• The cash cycle was shortened by 14.3 days to 32.4 days.
PHARMA DISTRIBUTION

11. Profarma | Histórico Alocação de Capital
Profarma
3Q17 | Key Highlights
11
SPECIALTIES
• Total sales rose by 1.3% year-over-year in 9M17.
• Operating expenses slid by 0.8 p.p., from 9.0% to 8.2%.
• Vaccine sales shot up by 25.7%.
• Average monthly sales per store increased by 112.9%
to R$353.4 thousand between 3Q17 and September
2016.
• Store expenses reduction from 30.0% to 26.7%,
quarter-over-quarter.
• Average EBITDA per month shot up by 91.1% from
December 2016.
REDE ROSÁRIO
d1000 VAREJO FARMA RJ
• Monthly sales per store came to R$579.0 thousand,
6.2% higher than ABRAFARMA’s (Brazilian Association
of Pharmacy and Drugstore Chains) average.
• Store expenses fell from 21.5% to 19.6%.
• The contribution margin of stores stood at 9.0%.

12. Consolidado | Receita Bruta
4.5%
Consolidated IFRS (R$ million)
Sales decreased by 6.6% year-over-year.
Distribuição Farma
Varejo
Profarma
Consolidated | Gross Revenues
12
Sales increased by 58,7% year-over-year
6.4%
2,840 2,720
599 940
965
1,022
910 908 901
198
241
307 318 314
3,439
3,659
1,163
1,263
1,217 1,226 1,216
Pharma Distribution Retail
9M16 1Q179M17 2Q174Q163Q16 3Q17

13. Consolidated IFRS (R$ million and % Net Income)
Consolidado | Ebitda e Margem Ebitda Ajustada
Profarma
Consolidated | Ebitda and Adjusted Margin Ebitda (Ex-Rosário)
13
60
20 20
23
17
93
54
20
-2
-3 -2
30
16
19
23
13
7
-2 -2 -3
4
-2
0 -1 0
-1
110
51
35
14
15
19
16
Pharma Distribution Retail Equity Income -SpecialtiesConsolidated Ex-Rosário
9M16 1Q179M17 2Q174Q163Q16 3Q17
1.6%
3.5%
1.5% 1.5%1.3%
3.7%
1.9%
1.9%
1.8% 1.9% 2.2% 1.7%

14. Consolidado | Ebitda e Margem Ebitda Ajustada
Profarma
Consolidated | Ebitda Bridge per Division 3Q17 vs 3Q16 (w/o Rosário)
14
Consolidated IFRS (R$ million and % Net Income)
Pharma
Distribution
3Q16 3Q17Equity Income
Specialties
d1000
RJ
Rosário
35.4
-16.9
-1.9
-1.7
1.0 15.8

15. Profarma
Consolidated | Capex and Indebtness
15
Capex
3Q17OthersIT
Machinery and
Equipment
Capex
(R$ million)
Net Debt and Net Debt / EBITDA
(R$ million)
3Q16 4Q16 2Q17 3Q171Q17
Ex-Rosário.
2Q16
397.8
428.4
3.8x
3.1x
326.0
397.1
2.5x
4.0x
353.2
2.7x
395.6
4.9x8.41.1
0.8
6.5

16. Consolidado | Lucro Líquido
Profarma
Consolidated | Adjusted Net Income (w/o Rosário)
16
Net Income Adjusted Net Income
3Q17 2.4
(35.3)
3Q16
(9.5)
0.7 1Q17
(1.4)
(27.1)
4Q16
(3.9)
(38.6)
2Q17 1.5
(24.8)
-0.9%
0.1%
-3.5%
-0.4%
-2.6%
-0.1%
-2.4%
0.1%
-3.4%
0.2%
Consolidated IFRS (R$ million and % Net Income)

17. Consolidado | Ebitda e Margem Ebitda Ajustada
Profarma
Consolidated | Adjusted Net loss Bridge 3Q17 vs 3Q16*
17
Consolidated IFRS (R$ million and % Net loss)
3Q16 3Q17
Ebitda
d1000
RJ
Ebitda
Pharma
Distribution
Ebitda
Rosário
Equity
Income
Specialties
Financial
Expenses
Retail Invest.
Non
Recurring
Expenses
Operating
Financial
Expenses
Income Tax /
Holdings /
Depreciation
Why?
Mainly due to the highest
price increase last 10 years
in 2016
Best Rosário
Ebitda since
acquisition
Almost flat
Mainly due
to Retail
reestructuri
ng,
Including 34
stores
closed
Financial
expenses
due to
Rosário
acquisition
Lower
interest
rates
Higher
operating
loss before
taxes

18. Attachments

19. Consolidado | Receita Bruta
Profarma
Consolidated | Gross Revenues
19
Consolidated IFRS (R$ million)
Pharma Distribution Retail
4.5%6.4%
2,840 2,720
599 940
965 1,022
910 908 901
198
241
307 318 314
3,439
3,659
1,163
1,263
1,217 1,226 1,216
9M16 1Q179M17 2Q174Q163Q16 3Q17

20. Consolidado | Lucro Bruto
Profarma
Consolidated | Gross Profit
20
Pharma Distribution Retail
284 256
181
281
94 88 82 93 81
60 72 96
93
93
465
537
154 160
178
186
173
9M16 1Q179M17 2Q174Q163Q16 3Q17
15.6%
17.2%
17.1% 17.8%
14.6%15.2%
16.6%
Consolidated IFRS (R$ million and % Net Income)

21. Consolidado | Despesas Operacionais SGA
Profarma
Consolidated | Operating Expenses - SGA
21
11,8% 11,8%
16,1%
15,0%14,0%
16,2%
15,8%
195 213
156
281
69 79 70 73 71
51
74 99 97
85
352
494
120
153
168 170
156
Pharma Distribution Retail
9M16 1Q179M17 2Q174Q163Q16 3Q17
Consolidated IFRS (R$ million and % Net income)

22. Consolidado | Ebitda e Margem Ebitda Ajustada
Profarma
Consolidated | Adjusted EBITDA and EBITDA Margin (w/o Rosário)
22
93
54
20
-2
-3 -2
30
16
19
23
13
7
-2 -2 -3
4
-2
0 -1 0
-1
110
50
35
14
15
19
16
Consolidated IFRS (R$ million e % Net income)
9M16 1Q179M17 2Q174Q163Q16 3Q17
1.6%
3.5%
1.5% 1.5%1.3%
3.7%
1.9%
60
20 20
23
17
Pharma Distribution Retail Equity Income SpecialtiesConsolidated Ex-Rosário
1.9%
1.8% 1.9% 2.2% 1.7%

23. Consolidado | Lucro Líquido
Profarma
Consolidated | Net Income (w/o Rosário)
23
Consolidated IFRS (R$ million and % Net Income)
Net lncome Adjusted Net Income
3Q17 2.4
(35.3)
3Q16
(9.5)
4.9
1Q17
(1.4)
(27.1)
4Q16
(3.9)
(38.6)
2Q17 1.5
(24.8)
-0.9%
0.5%
-3.5%
-0.4%
-2.6%
-0.1%
-2.4%
0.1%
-3.4%
0.2%

24. Profarma
Consolidated | Capex and Indebteness
24
Capex
3Q17OthersIT
Machinery and
Equipment
8.41.1
0.8
6.5
Capex
(R$ million)
2Q16 3Q16
397.8
428.4
3.8x
3.1x
Net Debt and
Net Debt / Ebitda (R$ milion)
1Q17
326.0
397.1
2Q17
2.5x
4.0x
4Q16
353.2
2.7x
Ex-Rosário.
395.6
3Q17
4.9x

25. Financial Data (R$ million and % Net Income)
Pharma Distribution
Financial Performance
25
1,136
1,041 1,042 1,0481,056 8.9
10.5 10.5
9.09.1
8.1
7.7
8.2
7.9
7.7
1.6
3.3
2.5
1.5
2.1
1Q17 2Q173Q16 4Q16 3Q17 1Q17 2Q173Q16 4Q16 3Q17 1Q17 2Q173Q16 4Q16 3Q17 1Q17 2Q173Q16 4Q16 3Q17
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)
Increase of 8.6% in the
segment of independent
customers;
Evolution of 44.6% in the
category of personal hygiene &
cosmetics;
Reduction of 14.3 days of the
cash cycle, which reached 32.4
days.

26. Especialidades
Crescimento de 6,3% nas vendas da
categoria de genéricos.
Financial Data (R$ million and % Net Income)
Operating Expenses Reduction
by 0.8 p.p., from 9,0% to 8,2%;
Specialties
Financial Performance
26
Increase of 25.7% in sales of
the vaccine category.
249.0
241.5 233.9 233.9
260.5
10.210.6
9.9 9.29.9 8.2
9.0
8.7
8.2
7.5
2.6
0.9 1.1
0.4
0.3
Total sale in 9M17 increased
1,3% when compared to the
same period of the previus
year;
1T17 2T173T16 4T16 3T17 1T17 2T173T16 4T16 3T17 1T17 2T173T16 4T16 3T17 1T17 2T173T16 4T16 3T17
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)

27. Varejo
202.4
Financial Data (R$ million and % Net Income)
Monthly sales per store came R$
569,8 Thousand, 8.5% higher than
ABRAFARMA’s average;
Store expenses fell from 21.8% to
20,9%;
198.1
200.0 201.0
d1000 varejo farma RJ
Financial Performance (w/o Rosário)
27
d1000 varejo farma RJ
Rosário
Same-Store Sales increased by 3%
against 2T17 and average
store/month sales 106.1% in the
comparison of Sep/2017 versus
Sep/16, reaching R$ 339.6
Thousand;
Reduction in store expenses, from
21.5% to 19.6%;
197.5
29.4
30.3
28.5 28.6
30.5
27.0
25.8
27.1
24.8
27.9
2.3
3.2
0.3
2.6
1.0 Contribution Margin reached 9.0%.
Evolution of 91.1% in the average
Ebitda/month compared to the
result of Dec/16;
1Q17 2Q173Q16 4Q16 3Q17 1Q17 2Q173Q16 4Q16 3Q17 1Q17 2Q173Q16 4Q16 3Q17 1TQ7 2Q173Q16 4Q16 3Q17
EBITDA Margin
(%)
Op. Exp. SG&A
(%)
Gross Margin
(%)
Gross Revenues
(R$ million)

28. d1000 varejo farma RJ
Operating Performance (w/o Rosário)
28
Total Sales Increased (%) Same Store Sales (%) SSS Mature Stores (%)
-2.3%
0.8%
2.2%
3Q16 1Q17 2Q174Q16
-2.2 p.p.
3.7%
1.5%
3Q17
-1.8%
1.4%1.4%
3Q16 1Q17 2Q174Q16
-0.1 p.p.3.9%
3.8%
3Q17
-3.0%
0.9%
0.0%
3Q16 1Q17 2Q164Q16
-0.3 p.p.2.5%
2.2%
3Q17

29. d1000 varejo farma RJ
Operating Performance (w/o Rosário)
29
5 aberturas
10 fechamentos
10 reformas
102 maduras
Monthly Average Store’s Sales (mature)
(R$ thousands) # of Stores (units) Average Ticket (R$)
3 opened
11 closed
7 reformed
101 mature
569.8
561.0
580.0
3Q16 1Q17 2Q174Q16
2.7%
564.0
579.0
3Q17
123123
129
3Q16 QT17 2Q174Q16
-6.9%
130
121
3T17
37.89
36.01
36.36
3Q16 1Q17 2Q174Q16
7.8%
35.83
38.62
3Q17

31. Max Fischer - CFO e IRO | Beatriz Diez - GRI
Tel.: 55 (21) 4009-0276 | E-mail: ri@profarma.com.br
www.profarma.com.br/ri